Dulaglutide for the treatment of type 2 diabetes

Mar 10, 2017Expert opinion on biological therapy

Dulaglutide as a treatment for type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Dulaglutide demonstrated better glucose control compared to other treatments in various patient populations.

Dulaglutide is a once-weekly GLP-1 receptor agonist used for hyperglycemia in type 2 diabetes.
In the phase-3 AWARD program, dulaglutide showed efficacy and safety compared to placebo and other glucose-lowering medications.
Both Caucasian and Japanese patients experienced improved glucose control with dulaglutide and minimal risk of hypoglycemia.
Patients treated with dulaglutide also experienced weight loss, although there was a higher dropout rate due to transient gastrointestinal side effects.
Dulaglutide was found to be non-inferior to liraglutide, with a safety profile similar to other GLP-1 receptor agonists.
The ongoing REWIND trial aims to establish dulaglutide's ability to reduce cardiovascular and diabetic complications.

AI simplified

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are injectable agents used for the treatment of hyperglycemia in type 2 diabetes. The interest for this pharmacological class is rising with the development of once weekly compounds and the demonstration of a potential reduction in cardiorenal outcomes. Areas covered: The paper describes the main pharmacokinetic/pharmacodynamic characteristics of dulaglutide, a new once-weekly GLP-1 RA. Dulaglutide was extensively investigated in the phase-3 AWARD program, which demonstrated its safety and efficacy when compared to placebo or active glucose-lowering agents in patients treated with diet alone, metformin or sulfonylurea monotherapy, oral dual therapies and basal insulin. In both Caucasian and Japanese patients, comparative trials showed better glucose control with dulaglutide, with a minimal risk of hypoglycemia and weight loss, but at the expense of an increased dropout rate due to side effects, mostly transient gastrointestinal disturbances. Dulaglutide proved its non-inferiority versus liraglutide and the safety and tolerance profile is similar to that of other GLP-1 RAs. Expert opinion: The once-weekly formulation and the combined positive effects on both glucose control and weight improves patient satisfaction despite nausea. Dulaglutide must prove its capacity to reduce cardiovascular and diabetic complications in the ongoing prospective REWIND trial.

Full Text

Full text is available at the source.

View full text ↗

Dulaglutide for the treatment of type 2 diabetes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief